尼妥珠单抗联合奈达铂化疗及调强适形放疗治疗局部晚期鼻咽癌的临床效果分析

Clinical Effect of Nimotuzumab Combined with Nedaplatin Chemotherapy and Intensity-modulated Radiotherapy in the Treatment of Locally Advanced Nasopharyngeal Carcinoma

目的:分析尼妥珠单抗联合奈达铂化疗及调强适形放疗(IMRT)治疗局部晚期鼻咽癌的临床效果。方法:选取2017年1月—2019年12月北海市人民医院收治的局部晚期鼻咽癌患者80例作为研究对象,随机分为对照组和试验组,各40例。对照组给予奈达铂化疗和IMRT,试验组在对照组基础上给予尼妥珠单抗治疗。比较两组治疗效果、远期生存率、肿瘤标志物水平、不良反应发生情况。结果:试验组治疗总有效率高于对照组,差异有统计学意义(P=0.025)。两组局部无复发生存率、远处无转移生存率、总生存率比较,差异无统计学意义(P>0.05);试验组无疾病生存率高于对照组,差异有统计学意义(P=0.013)。治疗前,两组糖抗原125(CA125)、细胞角蛋白19片段(CYFRA21-1)水平比较,差异无统计学意义(P>0.05);治疗后,两组CA125、CYFRA21-1水平均低于治疗前,且试验组低于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:尼妥珠单抗联合奈达铂化疗及IMRT治疗局部晚期鼻咽癌的临床效果显著,能够延长患者生存期,降低肿瘤标志物水平及不良反应发生率。

Objective:To analyze the clinical effect of Nimotuzumab combined with nedaplatin and intensity modulated conformal radiotherapy(IMRT) in the treatment of locally advanced nasopharyngeal carcinoma.Methods:A total of eighty patients with locally advanced nasopharyngeal carcinoma treated in Beihai People's Hospital from January 2017 to December 2019 were selected as the study objects and randomly divided into control group and experimental group,with forty patients in each group.The control group was given nedaplatin chemotherapy and IMRT,and the experimental group was given Nimotuzumab on the basis of the control group.The therapeutic effect,long-term survival rate,tumor marker level and adverse reactions were compared between the two groups.Results:The total effective rate of experimental group was higher than that of control group,the difference was statistically significant(P=0.025);there was no significant difference in local recurrence-free survival,distant metastasis-free survival and overall survival between the two groups(P>0.05);the disease-free survival rate of experimental group was higher than that of control group,and the difference was statistically significant(P=0.013);before treatment,there was no significant difference in the levels of glycoantigen 125(CA125) and cytokeratin 19 fragment(CYFRA21-1) between the two groups(P>0.05);after treatment,the levels of CA125 and CYFRA21-1 in 2 groups were lower than before treatment,and the experimental group was lower than the control group,the difference was statistically significant(P<0.05);there was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Nimotuzumab combined with nedaplatin chemotherapy and IMRT have significant clinical effects in the treatment of locally advanced nasopharyngeal carcinoma,which can prolong the survival period of patients,reduce the level of tumor markers and the incidence of adverse reactions.